Electrotransfer of human IL-1Ra into skeletal muscles reduces the incidence of murine collagen-induced arthritis

Journal of Gene Medicine

Volumn 6, Issue 10, 2004, Pages 1125-1133

  Jeong, Jae Gyun ^a   Kim, Jong Mook ^b   Ho, Seong Hyun ^b   Hahn, Woong ^b   Yu, Seung Shin ^b   Kim, Sunyoung ^a  

^a Seoul National University   (South Korea)

^b ViroMed Co Ltd   (South Korea)

Author keywords

Collagen induced arthritis; IL 1Ra; In vivo electroporation; Plasmid DNA; Skeletal muscle

Indexed keywords

COLLAGEN TYPE 2; COMPLEMENTARY DNA; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 1BETA; NAKED DNA; PLASMID DNA;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DNA SEQUENCE; ELECTRIC FIELD; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTROCNEMIUS MUSCLE; GENE EXPRESSION; GENE TRANSFER; GENETIC CODE; HISTOPATHOLOGY; IMMUNIZATION; IN VIVO STUDY; INCIDENCE; KNEE ARTHRITIS; MOUSE; MOUSE STRAIN; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SKELETAL MUSCLE; STATISTICAL SIGNIFICANCE; TAIL; TISSUE INJURY;

ANIMALS; ARTHRITIS; COLLAGEN; CYTOKINES; DNA; DNA, COMPLEMENTARY; ELECTROPORATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; JOINTS; KNEE JOINT; MICE; MICE, INBRED DBA; MUSCLE, SKELETAL; PLASMIDS; SIALOGLYCOPROTEINS; TIME FACTORS;

BOVINAE; MURINAE;

EID: 13644254726     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.599     Document Type: Article

References (50)

1. Dayer JM, Feige U, Edwards CK III, et al. Anti-interleukin-1 therapy in rheumatic diseases. Curr Opin Rheumatol 2001; 13: 170-176.
2. Lewthwaite J, Blake S, Thompson RC, et al. Antifibrotic action of interleukin-1 receptor antagonist in lapine monoarticular arthritis. Ann Rheum Dis 1995; 54: 591-596.
3. Wooley PH, Whalen JD, Chapman DL, et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 1993; 36: 1305-1314.
4. Schwab JH, Anderle SK, Brown RR, et al. Pro- and anti-inflammatory roles of interleukin-1 in recurrence of bacterial cell wall-induced arthritis in rats. Infect Immun 1991; 59: 4436-4442.
5. Bresnihan B. Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist. Ann Rheum Dis 1999; 58 Suppl 1): 196-98.
6. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196-2204.
7. Jiang Y, Genant HK, Watt I, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43: 1001-1009.
8. Bandara G, Mueller GM, Galea-Lauri J, et al. Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci U S A 1993; 90: 10 764-10 768.
9. Roessler BJ, Hartman JW, Vallance DK, et al. Inhibition of interleukin-1-induced effects in synoviocytes transduced with the human IL-1 receptor antagonist cDNA using an adenoviral vector. Hum Gene Ther 1995; 6: 307-316.
10. Bakker AC, Joosten LA, Arntz OJ, et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997; 40: 893-900.
11. Pan RY, Chen SL, Xiao X, et al. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum 2000; 43 289-297.
12. Kim SH, Lechman ER, Kim S, et al. Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis. Mol Ther 2002; 6: 591-600.
13. Nishikawa M, Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 2001; 12: 861-870.
14. Decrouy A, Renaud JM, Lunde JA, et al. Mini- and full-length dystrophin gene transfer induces the recovery of nitric oxide synthase at the sarcolemma of mdx4cv skeletal muscle fibers. Gene Ther 1998; 5: 59-64.
15. Tripathy SK, Svensson EC, Black HB, et al. Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc Natl Acad Sci U S A 1996; 93: 10 876-10 880.
16. Titomirov AV, Sukharev S, Kistanova E. In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA. Biochim Biophys Acta 1991; 1088: 131-134.
17. Heller R, Jaroszeski M, Atkin A, et al. In vivo gene electroinjection and expression in rat liver. FEBS Lett 1996; 389: 225-228.
18. Rols MP, Delteil C, Golzio M, et al. In vivo electrically mediated protein and gene transfer in murine melanoma. Nat Biotechnol 1998; 16: 168-171.
19. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998; 16: 867-870.
20. Mir LM, Bureau MF, Gehl J, et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci U S A 1999; 96: 4262-4267.
21. Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 1999; 6: 508-514.
22. Rizzuto G, Cappelletti M, Maione D, et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci U S A 1999; 96: 6417-6422.
23. Kreiss P, Bettan M, Crouzet J, et al. Erythropoietin secretion and physiological effect in mouse after intramuscular plasmid DNA electrotransfer. J Gene Med 1999; 1: 245-250.
24. Maruyama H, Sugawa M, Moriguchi Y, et al. Continuous erythropoietin delivery by muscle-targeted gene transfer using in vivo electroporation. Hum Gene Ther 2000; 11: 429-437.
25. Bigey P, Bureau MF, Scherman D. In vivo plasmid DNA electrotransfer. Curr Opin Biotechnol 2002; 13: 443-447.
26. Perez N, Plence P, Millet V, et al. Tetracycline transcriptional silencer tightly controls transgene expression after in vivo intramuscular electrotransfer: application to interleukin 10 therapy in experimental arthritis. Hum Gene Ther 2002; 13: 2161-2172.
27. Celiker MY, Ramamurthy N, Xu JW, et al. Inhibition of adjuvant-induced arthritis by systemic tissue inhibitor of metalloproteinases 4 gene delivery. Arthritis Rheum 2002; 46: 3361-3368.
28. Saidenberg-Kermanac'h N, Bessis N, Deleuze V, et al. Efficacy of interleukin-10 gene electrotransfer into skeletal muscle in mice with collagen-induced arthritis. J Gene Med 2003; 5: 164-171.
29. Kim JM, Ho SH, Hahn W, et al. Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion protein. Gene Ther 2003; 10: 1216-1224.
30. Lee Y, Park EJ, Yu SS, et al. Improved expression of vascular endothelial growth factor by naked DNA in mouse skeletal muscles: implication for gene therapy of ischemic diseases. Biochem Biophys Res Commun 2000; 272: 230-235.
31. Lim BK, Choe SC, Shin JO, et al. Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis. Circulation 2002; 105: 1278-1281.
32. Kim JM, Ho SH, Park EJ, et al. Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis. Arthritis Rheum 2002; 46: 793-801.
33. Apparailly F, Verwaerde C, Jacquet C, et al. Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. J Immunol 1998; 160: 5213-5220.
34. Mir LM, Bureau MF, Rangara R, et al. Long-term, high level in vivo gene expression after electric pulse-mediated gene transfer into skeletal muscle. C R Acad Sci III 1998; 321: 893-899.
35. Jaroszeski MJ, Gilbert R, Nicolau C, et al. In vivo gene delivery by electroporation. Adv Drug Deliv Rev 1999; 35 131-137.
36. Kim JM, Jeong JG, Ho SH, et al. Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist. Gene Ther 2003; 10: 1543-1550.
37. Arend WP, Malyak M, Guthridge CJ, et al. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16 27-55.
38. Joosten LA, Helsen MM, van de Loo FA, et al. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996; 39: 797-809.
39. Bendele A, McAbee T, Sennello G, et al. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999; 42: 498-506.
40. Morita Y, Yang J, Gupta R, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001; 107: 1275-1284.
41. van de Loo FA, van den Berg WB. Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators. Rheum Dis Clin North Am 2002; 28 127-149.
42. Tupin E, Poirier B, Bureau MF, et al. Non-viral gene transfer of murine spleen cells achieved by in vivo electroporation. Gene Ther 2003; 10: 569-579.
43. Ghivizzani SC, Lechnian ER, Kang R, et al. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci U S A 1998; 95: 4613-4618.
44. Kim KN, Watanabe S, Ma Y, et al. Viral IL-10 and soluble TNF receptor act synergistically to inhibit collagen-induced arthritis following adenovirus-mediated gene transfer. J Immunol 2000; 164: 1576-1581.
45. Hartikka J, Sukhu L, Buchner C, et al. Electroporation-facilitated delivery of plasmid DNA in skeletal muscle: plasmid dependence of muscle damage and effect of poloxamer 188. Mol Ther 2001; 4: 407-415.
46. Fewell JG, MacLaughlin F, Mehra V, et al. Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to muscle with electroporation. Mol Ther 2001; 3: 574-583.
47. Mennuni C, Calvaruso F, Zampaglione I, et al. Hyaluronidase increases electrogene transfer efficiency in skeletal muscle. Hum Gene Ther 2002; 13: 355-365.
48. Bureau MF, Gehl J, Deleuze V, et al. Importance of association between permeabilization and electrophoretic forces for intramuscular DNA electrotransfer. Biochim Biophys Acta 2000; 1474: 353-359.
49. Draghia-Akli R, Fiorotto ML, Hill LA, et al. Myogenic expression of an injectable protease-resistant growth hormone-releasing hormone augments long-term growth in pigs. Nat Biotechnol 1999; 17: 1179-1183.
50. Draghia-Akli R, Khan AS, Cummings KK, et al. Electrical enhancement of formulated plasmid delivery in animals. Technol Cancer Res Treat 2002; 1: 365-372.